Sevelamer treatment strategy in peritoneal dialysis patients: Conventional dose does not make best use of resources

Journal of Nephrology

Volumn 20, Issue 6, 2007, Pages 674-682

  Chow, Kai Ming ^a   Szeto, Cheuk Chun ^a   Kwan, Bonnie Ching Ha ^a   Leung, Chi Bon ^a   Li, Philip Kam Tao ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Incremental cost effectiveness ratio; K DOQI; Peritoneal dialysis; Phosphate binder; Sevelamer

Indexed keywords

CALCIUM; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; VITAMIN D;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HUMAN; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; KIDNEY FAILURE; LOW DRUG DOSE; MALE; MENTAL DISEASE; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; CHELATING AGENTS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERPHOSPHATEMIA; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PHOSPHORUS; POLYAMINES;

EID: 39449101846     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Chertow GM, Burker SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-14.
2. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-52.
3. Cizman B. Hyperphosphataemia and treatment with sevelamer in haemodialysis patients. Nephrol Dial Transplant 2003; 18 (Suppl 5): v47-9.
4. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 31: 458-82.
5. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 601-17.
6. Taal MW, Roe S, Masud T, Green D, Porter C, Cassidy MJ. Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney Int 2003; 63: 1116-20.
7. Shepherd J. Resource management in prevention of coronary heart disease: optimizing prescription of lipid-lowering drugs. Lancet 2002; 359: 2271-3.
8. Qunibi WY, Hootkins RE, McDowell EL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz ER, He DY, Nolan CR. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE) Study. Kidney Int 2004; 65: 1914-26.
9. McIntyre CW, Patel V, Taylor GS, Fluck RJ. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant 2002; 17: 1643-8.
10. Maher ER, Young G, Smyth-Walsh B, Pugh S, Curtis JR. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 1987; 2: 875-7.
11. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (Suppl 3): S1-201.
12. Beddhu S, Zeidel ML, Saul M, Seddon P, Samore MH, Stoddard GJ, Bruns FJ. The effects of comorbid conditions on the outcomes of patients undergoing peritoneal dialysis. Am J Med 2002; 112: 696-701.
13. Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK, Toto RD. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003; 23: 307-14.
14. Ubel PA, DeKay ML, Baron J, Asch DA. Cost-effectiveness analysis in a setting of budget constraints: is it equitable? N Engl J Med 1996; 334: 1174-7.
15. Manns B, Stevens L, Miskulin D, Owen WF Jr, Winkelmayer WC, Tonelli M. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 2004; 66: 1239-47.
16. Henderson J, Altmann P. Sevelamer. Nephron Clin Pract 2003; 94: c53-c58.
17. Lorenzo V, Martin-Malo A, Perez-Garcia R, Torregrosa JV, Vega N, de Francisco AL, Cases A. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study. Nephrol Dial Transplant 2006; 21: 459-65. Epub 2005 Nov 1.
18. Slatopolsky EA, Burke SK, Dillon MA, The RenaGel Study Group. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999; 55: 299-307.
19. Salusky IB, Goodman WG, Sahney S, Gales B, Perillous A, Wang HJ, Elashoff PM, Jüppner H. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 2005; 16: 2501-8.
20. Garland JS, Morton AR. Sevelamer hydrochloride in pentoneal dialysis patients: ca'canny but ca' awa'. Perit Dial Int 2006; 26: 300-5.